Discover
URGN
UroGen Pharma Ltd.
37.94
2 x 28.26
2 x 48.00
bid
ask
+
1.14
3.10%
2 @ 04:00 PM
37.94 +0.00 (0.00%)
| Ytd | 62.00% | |
| 1y | 191.40% |
37.11
day range
39.59
12.73
52 week range
39.59
| Open | 37.11 | Prev Close | 36.80 | Low | 37.11 | High | 39.59 | Mkt Cap | 1.85B |
| Vol | 1.09M | Avg Vol | 799.07K | EPS | -2.74 | P/E | N/A | Forward P/E | 29.95 |
| Beta | 1.62 | Short Ratio | 9.82 | Inst. Own | 100.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 29.01 | 200-d Avg | 22.75 | 1yr Est | 36.88 |
| Income Statement | |||
| Total Revenue | 50.96M | ||
| Revenues (USD) | 50.96M | ||
| Cost of Revenue | 4.14M | ||
| Gross Profit | 46.82M | ||
| Operating Expenses | 67.08M | ||
| Research and Development Expense | 15.60M | ||
| Selling, General and Administrative Expense | 51.49M | ||
| Operating Income | -20.26M | ||
| Interest Expense | 4.18M | ||
| Income Tax Expense | -4.77M | ||
| Net Income | -23.57M | ||
| Net Income Common Stock | -23.57M | ||
| Net Income Common Stock (USD) | -23.57M | ||
| Consolidated Income | -23.57M | ||
| Earnings per Basic Share | -0.47 | ||
| Earnings per Basic Share (USD) | -0.47 | ||
| Earnings per Diluted Share | -0.47 | ||
| Earning Before Interest & Taxes (EBIT) | -24.16M | ||
| Earning Before Interest & Taxes (USD) | -24.16M | ||
| Weighted Average Shares | 50.18M | ||
| Weighted Average Shares Diluted | 50.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 111.30M | ||
| Cash and Equivalents (USD) | 111.30M | ||
| Investments | 30.48M | ||
| Investments Current | 30.31M | ||
| Investments Non-Current | 177.00K | ||
| Trade and Non-Trade Receivables | 55.41M | ||
| Current Assets | 237.46M | ||
| Property, Plant & Equipment Net | 8.56M | ||
| Total Assets | 253.69M | ||
| Total Debt | 195.18M | ||
| Current Liabilities | 50.64M | ||
| Debt Non-Current | 195.18M | ||
| Total Liabilities | 377.94M | ||
| Accumulated Retained Earnings (Deficit) | -983.29M | ||
| Accumulated Other Comprehensive Income | 8.00K | ||
| Shareholders Equity | -124.25M | ||
| Shareholders Equity (USD) | -124.25M | ||
| Assets Non-Current | 16.23M | ||
| Total Debt (USD) | 195.18M | ||
| Inventory | 20.92M | ||
| Liabilities Non-Current | 327.31M | ||
| Trade and Non-Trade Payables | 35.35M | ||
| Tax Liabilities | 3.90M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 652.00K | ||
| Net Cash Flow from Financing | 65.20M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -800.00K | ||
| Capital Expenditure | -54.00K | ||
| Issuance (Purchase) of Equity Shares | 179.00K | ||
| Issuance (Repayment) of Debt Securities | 65.03M | ||
| Net Cash Flow from Investing | -20.69M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -20.63M | ||
| Net Cash Flow from Operations | -45.32M | ||
| Share Based Compensation | 4.63M | ||